ADC Therapeutics SA (ADCT)
ADC Therapeutics SA is a clinical-stage biotechnology company. It engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.
Address
BIOPOLE
EPALINGES, V8 1066
Founded
2011
Number of Employees
162
Website
http://www.adctherapeutics.com
Insider Transactions
Filters
Keyboard Shortcuts: Show (a) | Close (Esc)